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Abstract
Background: Nonviral vectors are attractively used for gene therapy owing to their distinctive advantages. Our previous
study has demonstrated that transfer of human IFNc gene into nasopharyngeal carcinoma (NPC) by using a novel nonviral
vector, minicircle (mc), under the control of cytomegalovirus (CMV) promoter was effective to inhibit tumor growth.
However, therapies based on CMV promoter cannot express the targeted genes in cancer tissues. Previous studies indicated
that the development of human NPC was closely associated with Epstein-Barr virus (EBV) and demonstrated the
transcriptional enhancer function of oriP when bound by EBV protein. Therefore, the present study is to explore the
targeted gene expression and the anti-tumor effect of a novel tumor-specific gene therapeutic system (mc-oriP-IFNc)i n
which the transgene expression was under the transcriptional regulation of oriP promoter.
Methodology/Principal Findings: Dual-luciferase reporter assay and ELISA were used to assess the expression of luciferase
and IFNc. WST assay was used to assess the cell proliferation. RT-PCR was used to detect the mRNA level of EBNA1. RNAi was
used to knockdown the expression of EBNA1. NPC xenograft models in nude mice were used to investigate the targeted
antitumor efficacy of mc-oriP-IFNc. Immunohistochemistry was used to detect the expression and the activity of the IFNc in
tumor sections. Our results demonstrated that mc-oriP vectors mediated comparable gene expression and anti-proliferative
effect in the EBV-positive NPC cell line C666-1 compared to mc-CMV vectors. Furthermore, mc-oriP vectors exhibited much
lower killing effects on EBV-negative cell lines compared to mc-CMV vectors. The targeted expression of mc-oriP vectors was
inhibited by EBNA1-siRNA in C666-1. This selective expression was corroborated in EBV-positive and -negative tumor
models.
Conclusions/Significance: This study demonstrates the feasibility of mc-oriP-IFNc as a safe and highly effective targeted
gene therapeutic system for the treatment of EBV positive NPC.
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Introduction
The goal of cancer treatment is to selectively eliminate
malignant cells while leaving normal tissues intact [1]. Therefore,
targeted strategies are needed to be implemented for future
therapies to ensure efficient activity at the site of patients’ primary
tumors or metastases without causing intolerable side effects. To
this end, cellular mechanisms of gene regulation have been
successfully exploited to direct therapeutic gene expression into
cancer cells [2,3,4]. Transcriptional targeting is feasible because
the tissue- or cancer-specific promoter can be activated in the
targeted cancer cells in the presence of proper subset of activators
while remaining silent in the non-targeted cells [5].
Nasopharyngeal carcinoma (NPC) is prevalent in South China,
North Africa, and among Alaskan Eskimos. A unique feature of
NPC is that nearly 100% of anaplastic or poorly differentiated
nasopharyngeal carcinomas contain Epstein-Barr virus genomes
and express EBV proteins [6], which are expressed exclusively in
the malignant tissues but not in the surrounding normal tissues.
This difference provides an exploitable opportunity for tumor-
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viral protein, Epstein-Barr Nuclear Antigen 1 (EBNA1), and one
region of the viral genome, termed latent origin of plasmid
replication (oriP), as being necessary and sufficient for replication
of the viral plasmid. Previous studies have determined that EBNA1
is essential for regulating the transcription of the transforming
genes of EBV [7,8,9]. Additionally, EBNA-1, the only viral protein
required for the replication of EBV in latently-infected cells, is
found in all EBV-associated malignancies [10]. The oriP is
composed of two separable cis elements, the Family of Repeats
(FR) and Dyad Symmetry element (DS) [11]. The FR element
consists of 20 tandem 30-bp repeats and acts as a transcriptional
enhancer for heterologous promoters when it is bound by EBNA1.
Based on these features, the oriP-CMV promoter has been
exploited for targeted gene therapy in EBV-positive NPC [12].
Our laboratory has investigated the potential effect of
minicircle-mediated IFNc gene therapy in human nasopharyngeal
carcinoma. Our data indicated that IFNc gene transfer produced
an antiproliferative effect on NPC cells in vitro and a profound
antitumor effect in vivo [13,14]. We also demonstrated that
minicircle-CMV-IFNc was more efficient than corresponding
conventional plasmids due to its capability of mediating long-
lasting, high level of IFNc gene expression [13]. The CMV
promoter, however, is ubiquitously expressed without tumor-
targeting activity; thus the application of this promoter is limited
due to the potential side effects caused by unwanted expression of
a therapeutic gene in normal tissues [15]. Furthermore, the
persistence of transgene expression from the minicircle can be
achieved in cells with low turnover rates, such as hepatocytes and
skeletal muscle cells [16]. These issues are especially critical when
the therapeutic gene is delivered systemically, such as by
intravenous injection.
To solve these problems, we have developed a novel minicircle
(mc) vector in which transgene expression is under the transcrip-
tional regulation of the oriP-CMV promoter (hereinafter to be
referred as oriP promoter). The binding of EBNA1 to the FR
domain in oriP region activates the transcription of downstream
genes. Selective expression of the therapeutic gene is successfully
achieved both in vitro and in vivo, indicating the feasibility of mc-
oriP-IFNc as a safe and highly effective gene therapy system for the
treatment of NPC. To our knowledge, this is the first report on a
non-viral minicircle vector used in targeted gene therapy and is the
first time that the oriP promoter has been combined with the
minicircle system for NPC-targeted therapy. This strategy lays the
foundation for targeted gene therapy of metastatic NPC by
intravenous delivery of therapeutic genes.
Results
Selective expression of luciferase in EBV-positive C666-1
cells mediated by oriP-vectors
To determine the transgene expression provided by the novel
EBNA1-regulated minicircle vectors in EBV-negative cells (293,
NP69, CNE-1 and CNE-2 cells) and the only available EBV-
positive NPC cell line (C666-1), the minicircle-luci was compared
with its parent plasmid p2WC31-luci and the intermediate plasmid
from which p2WC31-luci was derived (pSP72). All these plasmids
contained a luciferase expression cassette driven by an oriP
promoter or cytomegalovirus promoter (Figure 1A). Luciferase
activity was assessed 48 h (72 h for C666-1 since its low growth
rate) after transfection using the dual-luciferase reporter assay
system. Luciferase activities were 10–60 fold lower when driven by
oriP promoter than by CMV promoter in EBV-negative cells
(p,0.001; Figure 2A). In contrast, luciferase activity was 2–5 fold
higher when driven by oriP promoter than by CMV promoter in
the EBV-positive C666-1 cells (p,0.01; Figure 2A). Occasionally,
low levels of luciferase activity were detected in some EBV-
negative cells when driven by the oriP promoter, which suggested
the basal expression induced by the minimal CMV IE promoter
included in oriP promoter. This observation is consistent with a
previous study [12]. The expression levels of the minicircle groups
were significantly higher than those of the corresponding parent
groups, demonstrating that the minicircle is more efficient in
mediating transgene expression in vitro.( p,0.05; Figure 2A). There
was no consistent difference when minicircle groups were
compared with pSP72 groups in different cell lines in the short
term (48 hrs or 72hrs), which may be due to the size of the pSP72
vector is close to the minicircle vector.
Selective expression of IFNc in EBV-positive C666-1 cells
mediated by oriP-vectors
To investigate whether mc-oriP-IFNc can mediate efficient
expression of the IFNc gene in EBV-positive NPC cells, the
minicircle-IFNc was compared with its parent plasmid p2WC31-
IFNc and the intermediate plasmid from which p2WC31-IFNc was
derived (pSP72). All of these plasmids contained an IFNc
expression cassette driven by an oriP promoter or CMV promoter
(Figure 1A). 293 cells, NP69 cells, and three NPC cell lines were
transfected according to the regimen shown in Table 1. The
culture supernatant of each treatment was collected to investigate
the cumulative production of IFNc over the indicated time course
using ELISA. No IFNc was found in the culture medium from
p2WC31-transfected cells (data not shown). The expression level of
IFNc was obviously lower when driven by oriP promoter than by
CMV promoter in EBV-negative cells (p,0.05; Figure 2B).
However, there was no significant difference in IFNc expression
level when driven by the oriP or CMV promoter in EBV-positive
C666-1 cells (p.0.05; Figure 2B). The expression levels of the
minicircle groups were significantly higher than those of the
corresponding parent plasmid groups (p,0.05; Figure 2B). There
was no consistent difference when the minicircle groups were
compared with the pSP72 groups in different cell lines.
Mc-oriP-IFNc selectively inhibits the growth of EBV-
positive C666-1 cells
The killing effects of mc-oriP-IFNc on NPC cells compared with
mc-CMV-IFNc were assessed using the WST assay. The WST
assay was performed with Cell Counting Kit-8 (CCK-8) by using
Dojindo’s highly water-soluble tetrazolium salt WST-8. WST-8 is
reduced by dehydrogenases in cells to give a yellow colored
product (formazan), which is soluble in the tissue culture medium.
The amount of the formazan dye generated by the activity of
dehydrogenases in cells is directly proportional to the number of
living cells. The detection sensitivity of CCK-8 is higher than other
tetrazolium salts such as MTT, XTT, MTS or WST-1 (Cell
Counting Kit-8 Technical Manual). Transfection of NPC cells
with the mc-CMV-IFNc resulted in significantly reduced cell
viability in both EBV-negative cells (CNE-1, CNE-2) and EBV-
positive C666-1 cells (p,0.05; Figure 3). However, mc-oriP-IFNc
caused a significant reduction of C666-1 cell viability but no
impact on EBV-negative cells. Treatment of C666-1 cells with mc-
oriP-IFNc or mc-CMV-IFNc achieved a similar extent of toxicity
(relative growth rate of 48.8961.7% and 46.8962.07%, respec-
tively; p.0.05), suggesting that the two promoters provided
comparable levels of transgene expression. These results are
consistent with previous observations reported by Li et al [12].
Furthermore, the minicircle showed more profound effects than
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growth inhibitory effect was observed in 293 and NP69 cells
treated with IFNc gene transfer (p.0.05).
The oriP-based promoter is responsive to EBNA1
Although endpoint PCR is at best only semi-quantitative, we
observed a distinct increase in EBNA1 mRNA level following
overexpression (p,0.05; Figure 4A) and a clear decrease following
siRNA treatment (p,0.05; Figure 4B). To further verify whether
the targeted gene expression of oriP promoter was regulated by
EBNA1 and transient expression of EBNA1 was sufficient to
enhance the luciferase activity of the mc-oriP-luci treatment group,
the following experiments were performed. EBV-negative CNE-2
cells were pre-transfected with an EBNA1 expression plasmid,
followed by a second round of transfection with mc-oriP-luci 48 hrs
later. EBNA1 expression increased the luciferase activity in the
mc-oriP-luci treatment group (p,0.01; Figure 4C) while had no
effect on the luciferase activity in the mc-CMV-luci treatment
group (p.0.05; Figure 4C). The EBV-positive C666-1 cells were
treated with siRNA to down-regulate EBNA1 expression. EBNA1
silencing reduced the luciferase activity in the mc-oriP-luci
treatment group (p,0.0001; Figure 4D) with no effect on the
luciferase activity in the mc-CMV-luci treatment group (p.0.05;
Figure 4D).
Targeted efficacy of mc-oriP-IFNc on nasopharyngeal
xenograft tumors
To determine whether the in vitro data of selective expression of
the oriP-driven minicircle vector can be corroborated in a more
complex in vivo model, CNE-2 (EBV-negative) and C666-1 (EBV-
positive) tumors were treated with either mc-oriP-IFNc or mc-
CMV-IFNc. Each mouse was treated with intratumoral injection
of 100 ml plasmid-liposome complex containing 15 mg DNA and
60 ml lipofectamine 2000 once a week for 3 weeks (as shown in
Table 1). The time-dependent evolution of tumor volume in mice
inoculated with CNE-2 and C666-1 cells (Figure 5A and B)
indicated that treatment with mc-oriP-IFNc had minimal inhib-
itory effect on EBV-negative CNE-2 tumors compared with the
control p2WC31 group (Figure 5A). In contrast, the tumor size of
EBV-positive C666-1 xenografts treated with mc-oriP-IFNc was
significantly decreased compared with control groups (p,0.05;
Figure 5B). Furthermore, mc-oriP-IFNc treatment had similar
effect on EBV-positive C666-1 tumors compared to mc-CMV-
IFNc treatment (p.0.05).
The inhibition rate of the treated group was determined
according to tumor weight (Figure 5C and D), and the growth of
tumors after mc-oriP-IFNc or mc-CMV-IFNc treatment was
significantly slower than those of the control groups (p,0.05). In
the CNE-2 cell-xenografted models, the inhibition rates of
Figure 1. Schematic diagram of the construction of mc-oriP and control vectors and the generation of mc-oriP-IFNc. (A) Diagram of
the minicircle vectors carrying the IFNc gene or firefly luciferase gene under the control of the oriP promoter (left) or CMV promoter (right). (B) Flow
chart of FC31 integrase-mediated intramolecular recombination of p2FC31-oriP-IFNc. The resulting product is minicircle-oriP-IFNc. Amp, ampicillin
resistance gene; BAD, araBAD promoter; araC, araC repressor; attB, bacterial attachment site; attP, phage attachment site; attR, right hybrid sequence;
I-SceIg, I-SceI gene; I-SceIs, I-SceI cutting site; L-arab., L-arabinose.
doi:10.1371/journal.pone.0019407.g001
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PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19407Figure 2. Selective expression of luciferase or IFNc gene mediated by mc-oriP vector in EBV-positive cells. (A) Luciferase activities were
assayed using the Dual-Luciferase Reporter Assay System for EBV-negative cell lines (293, NP69, CNE-1 and CNE-2) and the EBV-positive cell line (C666-1). (B)
The expressionlevel of IFNcin the supernatant of different cells transfected with plasmids carrying the humanIFNcexpressioncassette as detected by anELISA
kit. Columns, mean of three independent experiments; bars, SD; *, p,0.05, gene expression under the control of oriP promoter compared with CMV promoter.
doi:10.1371/journal.pone.0019407.g002
Minicircle-Mediated Targeted Gene Therapy for NPC
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19407p2WC31-CMV-IFNc and mc-CMV-IFNc groups were 46.57%
and 74.6%, respectively (Figure 5C). For the C666-1 cell-
xenografted models, the inhibition rates in the p2WC31-oriP-
IFNc,p 2 WC31-CMV-IFNc, mc-oriP-IFNc and mc-CMV-IFNc
groups were 40.05%, 39.75%, 83.01%, and 82.05%, respectively
(Figure 5D). In both models, the minicircle group showed more
profound antitumor potential than the parent plasmid-treated
group (p,0.05; Figure 5C and D).
The long-term outcome of IFNc gene transfer was evaluated by
the survival rates of mice, using the protocol outlined in Table 1.
There was no additional treatment after three weeks of treatment.
For CNE-2 cell-xenografted mice, the median survival of the
p2WC31, p2WC31-oriP-IFNc,p 2 WC31-CMV-IFNc, mc-oriP-IFNc
and mc-CMV-IFNc groups was 3362.828, 3662.739, 4762.828,
3663.536, and 6666.364 days, respectively (Figure 5E). For
C666-1 cell-xenografted mice, the corresponding median survivals
were 3563.536, 4564.243, 4763.3, 6366.364, and 6364.243
days, respectively (Figure 5F). In both models, the minicircle group
had a longer survival duration than the parent plasmid-treated
group (p,0.05; Figure 5E and F).
Selective expression in EBV-positive C666-1 tumors
mediated by mc-oriP vectors
To assay the targeted expression of mc-oriP-IFNc in vivo, IFNc
protein levels were analyzed in tumor and liver using a human
IFNc ELISA kit. Intratumoral expression of mc-oriP-IFNc was
detected only in the EBV-positive C666-1 tumor, compared with
mc-CMV-IFNc treatment (p.0.05; Figure 6A and B). Systemic
(liver) expression of mc-oriP-IFNc was not detected in mice
bearing either the EBV-negative CNE-2 tumor or the EBV-
positive C666-1 tumor, compared with mc-CMV-IFNc treatment
(p,0.01). However, in mc-CMV-IFNc treatment groups, mice
bearing the CNE-2 tumor had much higher expression level of
IFNc in their livers than those bearing the C666-1 tumor
(Figure 6A and B).
To further verify the above result of different expressions in liver
mediated by the mc-CMV vector, we detected the expression of
luciferase gene carried by minicircle in liver and tumor tissues
through immunohistochemistry. Consistent with the above result,
in mc-oriP-luci treatment groups, the staining of luciferase was
observed only in the EBV-positive C666-1 tumor but neither in
the EBV-negative CNE-2 tumor nor in all livers of mice tested.
However, in mc-CMV-luci treatment groups, the staining of
luciferase was observed both in the EBV-positive C666-1 tumor
and in the EBV-negative CNE-2 tumor. Liver staining of mc-
CMV-luci was observed mainly in the mice bearing the EBV-
negative CNE-2 tumor (Figure S1). The result is similar to
previous report [12].
Intratumoral injection of mc-oriP-IFNc results in
significant IRF-1, p21 and BAK staining only in the EBV-
positive C666-1 tumor
We have demonstrated that IFNc can effectively activate IRF-1
and lead to the inhibition of cell proliferation and the stimulation
of cell apoptosis in NPC (unpublished data). IFNc-induced G0/G1
Table 1. Treatment regimens for in vitro and in vivo transfections.
Treatment regimen used for transfected cells
(1 mg DNA +1 ml lipofectamine 2000/well)
Group (in vitro)
Treatment regimen used for NPC-xenografted mice
(15 mg DNA +60 ml lipofectamine 2000
*/mouse)
Group (in vivo)
pSP72-oriP-IFNc/luci
pSP72-CMV-IFNc/luci
p2WC31-oriP-IFNc/luci
p2WC31-CMV-IFNc/luci
minicircle-oriP-IFNc/luci
minicircle-CMV-IFNc/luci
p2WC31
p2WC31-oriP-IFNc
p2WC31-CMV-IFNc
minicircle-oriP-IFNc
minicircle-CMV-IFNc
p2WC31
*0.9% NaCl solution was added to adjust the total volume to 100 ml. Each mouse was treated with intratumoral injection of plasmid-liposome complex once a week for
3 weeks.
doi:10.1371/journal.pone.0019407.t001
Figure 3. Minicircle-oriP-IFNc selectively inhibits the growth of
EBV-positive C666-1 cells in vitro. Cells were treated with minicircle-
IFNc or control plasmids for 48 hours (72 hours for C666-1). Cell viability
was determined by WST assay. Data are given as relative growth rates
compared with the p2FC31-treated group. Columns, mean of three
independent experiments; bars, SD; #, p,0.05, compared with the
p2FC31-treated group; *, p,0.05, gene expression under the control of
oriP promoter compared with CMV promoter.
doi:10.1371/journal.pone.0019407.g003
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and upregulation of Bak, respectively (unpublished data). Thus,
immunohistochemistry was used to detect the expression of IRF-1,
p21 and BAK. The intratumoral injection of mc-CMV-IFNc
resulted in significant IRF-1, p21 and BAK staining in both the
EBV-negative CNE-2 and the EBV-positive C666-1 tumors,
demonstrating that the expression of IFNc mediated by the
minicircle activated the downstream pathway of IFNc (Figure 6C).
In contrast, injection of mc-oriP-IFNc resulted in obvious IRF-1,
p21 and BAK staining only in the EBV-positive C666-1 tumor.
Minicircle mediates more robust antitumor effect than
conventional plasmid
In order to compare the antitumor effects of minicircle and its
derived plasmid pSP72 in vivo, C666-1 cell-xenografted mice were
treated with mc-oriP-IFNc and pSP72-oriP-IFNc. Treatment
regimen was conducted with the same protocol as shown in
Table 1. Our results indicated that mc-oriP-IFNc could mediate
more robust antitumor effect than pSP72-oriP-IFNc at days 16
and 21 (p,0.05) (Figure S2).
Discussion
Minicircle-mediated gene therapeutic techniques shown in
previous studies were non-specific, which limited their application
due to the potential systemic side effects. We report here for the
first time both the non-viral minicircle vector used in targeted gene
therapy and the combination of oriP promoter with minicircle
system for NPC- targeted therapy. Our findings demonstrate that
mc-oriP-IFNc induces antiproliferation of EBV-positive tumor
cells, represses tumor growth, and prolongs the mouse life span in
a manner as effective as that of mc-CMV-IFNc in vitro and in vivo.
In addition, mc-oriP-IFNc had minimal or no killing effects on
EBV-negative tissues. Therefore, this study indicates the feasibility
of mc-oriP-IFNc as a safe and highly effective gene therapy system
for NPC treatment.
Nasopharyngeal carcinoma has been shown to be the human
tumor showing the most consistent association with EBV [8].
Utilization of molecules uniquely present within a tumor cell to
elicit a cytotoxic response is an attractive strategy for the
development of new approaches to the targeted therapy of
neoplasia. The oriP promoter has been demonstrated to be very
powerful in inducing targeted gene expression [12,17,18,19,20]. In
previous studies, the oriP promoter was placed in adenovirus
vectors, which achieved very high transduction efficiencies.
Although viral-based systems have shown high transfection
efficiencies in vivo, they have serious disadvantages such as
immunogenicity and inflammatory responses [21].
Non-viral gene delivery strategies are usually based on plasmid
DNA carrying the gene of interest. Conventional plasmid vectors
include a bacterial backbone and a transcription unit. These
sequences, however, may cause undesirable effects such as the
production of antibodies against bacterial proteins expressed
from cryptic upstream eukaryotic expression signals, changes
in eukaryotic gene expression caused by antibiotic resistance
markers, and immune responses to CpG sequences [22]. Com-
pared to conventional plasmids, minicircle DNAs devoid of
plasmid bacterial sequences are superior as non-viral DNA vector
for multiple reasons: (a) relative safety due to the reduced numbers
of inflammatory unmethylated CpG motifs; (b) more efficient
Figure 4. Transcriptional expression and function of EBNA1 in EBV-negative (CNE-2) and -positive (C666-1) NPC cell lines. (A, B)
Reverse transcription-PCR analysis of EBNA1. A: CNE-2 cells were transiently transfected with plasmid expressing EBNA1 or control plasmid. For
quantitative analysis, pLNCX2-EBNA1 group was normalized to 1; B: C666-1 cells were treated with siRNA against GFP (siGFP) or EBNA1 (siEBNA1). For
quantitative analysis, siEBNA1 group was normalized to 1. (C, D) Luciferase activity was assayed in overexpressing EBNA1 (CNE-2) or silencing EBNA1
expression (C666-1) cell lines followed by transfection with mc-oriP-luci or mc-CMV-luci. Columns, mean of three independent experiments; bars,
SD;*, p,0.05.
doi:10.1371/journal.pone.0019407.g004
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and persistent transgene expression [16,23,24]. Previous studies
have demonstrated that the use of minicircles may offer a
promising avenue for safe and efficacious non-viral-based gene
therapies [25,26,27,28]. Based on these superior attributes, we
developed a recombinant minicircle vector carrying the human
IFNc gene that had antiproliferative and antitumor effects against
NPC in vitro and in vivo and also demonstrated that the
antiproliferative effects of IFNc gene transfer on NPC cell lines
could be attributed to G0-G1 arrest and apoptosis [13].
Figure 5. Selective antitumor effects of mc-oriP-IFNc on the growth of NPC xenografts and survival analysis. (A, B) Time-dependent
evolution of tumor volume in mice inoculated with the CNE-2 and C666-1 cell lines (n=6, each group). For CNE-2 cell-xenografted mice, mc-oriP-IFNc
or p2WC31-oriP-IFNc versus p2WC31, p.0.05; mc-CMV-IFNc versus p2WC31, p,0.05 at days 9, 13, 17, and 21; p2WC31-CMV-IFNc versus p2WC31,
p,0.05 at days 13, 17, and 21. For C666-1 cell-xenografted mice, mc-oriP-IFNc versus p2WC31, p,0.05 at days 11, 16, and 21; mc-CMV-IFNc versus
p2WC31, p,0.05 at days 11, 16, and 21; p2WC31-oriP-IFNc versus p2WC31, p,0.05 at days 16, and 21; p2WC31-CMV-IFNc versus p2WC31, p,0.05 at
days 16 and 21; mc-oriP-IFNc versus mc-CMV-IFNc, p.0.05. (C, D) Specific antitumor effects of mc-oriP-IFNc on C666-1 cell-xenografted nude mice
(n=6, each group). Mice were sacrificed after three weeks of treatment, and tumors were resected and weighted. Columns, mean of six mice; bars,
SD; #, p,0.05, compared with p2FC31-treated group; *, p,0.05, gene expression under the control of oriP promoter compared with CMV promoter.
(E, F) Effect of mc-oriP-IFNc on survival (n=8). For CNE-2 cell-xenografted mice, mc-oriP-IFNc versus p2WC31, p=0.066; mc-CMV-IFNc versus p2WC31,
p,0.0001. For C666-1 cell-xenografted mice, mc-oriP-IFNc versus p2WC31, p,0.0001; mc-oriP-IFNc versus mc-CMV-IFNc, p=0.368 (Kaplan-Meier).
doi:10.1371/journal.pone.0019407.g005
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minicirclevectorused inthecurrent studywasconstructedsuchthat
the CMV enhancer promoter was replaced with the oriP-CMV
promoter. The new promoter provides significantly higher levels of
luciferase reporter gene expression in EBV-positive NPC cells
compared with CMV promoter (p,0.05; Figure 2A). Although the
results of IFNc gene expression are consistent with those of the
reporter gene in EBV-negative cells, there was no significant
difference between the mc-oriP-IFNc-treated and the mc-CMV-
IFNc-treated groups in EBV-positive C666-1 cells, indicating
approximately equivalent levels of IFNc gene expression and
cytotoxicity between the respective mc-oriP and mc-CMV vectors
in the C666-1 cells (p.0.05; Figures 2B and 3). One explanation for
these observations is that the expression of different genes is variable
and consequently, the cell number for IFNc gene expression was
decreased after the cytotoxicity caused by IFNc.
In the present study, the overexpression of the EBNA1 gene in
CNE-2 cells resulted in an increase in luciferase activity in the mc-
oriP-luci treatment group (Figure 4C). Inhibition of EBNA1
expression in C666-1 cells by EBNA1-specific siRNA subsequently
reduced the luciferase activity in the mc-oriP-luci treatment group
but had no effect on the mc-CMV-luci treatment group
(Figure 4D). We and others have consistently demonstrated that
the oriP-based promoter specifically responds to EBNA1
[12,18,19,20]. Therefore, the tumor-specific promoter oriP can
be used for gene therapy in EBV-associated diseases, such as
Burkitt’s lymphoma (BL), Hodgkin’s disease (HD), and post-
transplant lymphoproliferative disorders (PTLD).
In addition to investigating the selective antiproliferation effects
of mc-oriP-IFNc in vitro, the targeted antitumor effects of mc-oriP-
IFNc were assessed in NPC-xenografts. The fact that the in vitro
data could be replicated in in vivo tumor models is exciting. Our
data show that the antitumor effects and survival rates were similar
between the mc-oriP-IFNc-treated and mc-CMV-IFNc-treated
groups in the C666-1 tumor model (p.0.05; Figure 5). However,
the oriP promoter was much less active in the EBV-negative CNE-
Figure 6. Tissue expression of IFNc and immunohistochemical analysis. (A, B) Expression level of IFNc in tumor and liver tissue. Results are
given in ng/mg of tissue. Columns, mean of three mice; bars, SD. (C) Representative immunostaining of IRF-1, p21 and BAK in CNE-2 cell- and C666-1
cell-xenografted tumors treated with mc-oriP-IFNc or mc-CMV-IFNc, respectively. Mice were sacrificed after three weeks of treatment, and tumors
were resected and frozen for immunohistochemistry assays. IRF-1 staining shows cytoplasmic and nuclear staining, p21 staining shows nuclear
staining, and BAK staining shows cytoplasmic staining. In the mc-oriP-IFNc-treated group, intense IRF-1, p21 and BAK staining were observed only in
EBV-positive C666-1 tumors. Tissue sections are shown at 6400 magnification. Scale bar represents 50 mm.
doi:10.1371/journal.pone.0019407.g006
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reduced survival rate (p.0.05; Figure 5). Again, the minicircle was
much more efficient than the parent plasmid p2FC31 and
conventional plasmid pSP72 (p,0.05; Figure 5 and Figure S2), this
may be due to the fact that minicircle DNA does not contain
extraneous plasmid backbone sequences that could cause tran-
scriptional repression in vivo [23,29], which is consistent with
previous studies [13,30,31].
Transgene expression can be detected in the host liver with
extensive intratumoral injection of the mc-CMV-IFNc (Figure 6A
and B), which raises a concern about potential systemic
cytotoxicity. Furthermore, there is a big difference in expression
of mc-CMV-IFNc in the livers of mice carrying different tumors.
However, the reason for this unexpected result is unclear. A
possible explanation is that the tissues of CNE-2 tumors that had
higher amount of stroma are looser and softer than those of C666-
1 tumors, which in turn may result in more minicircle DNAs in
liver probably by the leakage. The underlying mechanism needs
further to be elucidated. In addition, transgene expression in the
mc-oriP-IFNc-treated groups has not been detected in liver tissues
(Figure 6A and B). These results provide support for the mc-oriP-
IFNc plasmid as a promising and NPC-specific vector for gene
therapy. The minicircle vector is also a versatile tool to carry other
tissue- or cancer-specific promoters for the development of
promising therapeutics for other diseases.
Orthotopic models of many tumor types have been developed in
which metastasisoccursinasimilarmannerasinpatients[32].Data
on orthotopichumanNPCmodels, however, arestilllimited. Inone
report investigating this issue, a fluorescent orthotopic NPC
metastatic model was established in nude mice using stable and
high GFP-expressing NPC cell lines. This model will be useful for
understanding the biology of metastatic NPC and for discovering
effective therapies for this disease [33]. The next step in developing
the oriP-based minicircle system will be to investigate its antimeta-
static effect on the orthotopic human NPC model in nude mice.
This study will lay the foundation for targeted gene therapy of
metastatic NPC by intravenous delivery of a therapeutic gene.
Materials and Methods
Cells and culture conditions
The cell lines used in this study were 293 (human embryonic
kidney cell line, EBV negative), NP69 (immortalized human
nasopharyngeal epithelial cell line, EBV negative), CNE-1 (well-
differentiated NPC cell line, EBV negative), CNE-2 (poorly-
differentiated NPC cell line, EBV negative), and C666-1
(undifferentiated and the only available EBV positive NPC cell
line) [34,35]. CNE-1, CNE-2 and C666-1 cells were maintained in
RPMI 1640 containing 100 units/mL penicillin, 100 mg/mL
streptomycin, and 10% fetal bovine serum (Gibco, Paisley, United
Kingdom) at 37uC in a 5% CO2 humidified atmosphere. NP69
cells were maintained in Keratinocyte-SFM (Gibco, Invitrogen,
Cat.10724), and the experiments were conducted when the cells
were in an exponential growth phase. C666-1 is a kind gift from
Dr. Saiwah Tsao (University of Hong Kong, Hong Kong, PR
China). NP69 was kindly provided by Professor Musheng Zeng
(State Key Laboratory of Oncology in South China, Cancer
Center, Sun Yat-sen University, Guangzhou, PR China). 293,
CNE-1, and CNE-2 cell lines were maintained by our lab [13].
Construction of recombinant parent plasmids
Plasmid p2FC31 (9.7 kb) was a kind gift from Dr. Zhiying Chen
(Stanford University, Stanford, CA) [24]. Plasmid PDC312.
oriP.luc (6 kb) carrying the oriP-CMV promoter was provided
by Dr. FeiFei Liu (Department of Radiation Oncology, Princess
Margaret Hospital University Health Network, Toronto, Ontario,
Canada) [12]. pShuttle-IFNc (4.6 kb) carrying the human IFNc
expression cassette was constructed by our lab. pSP72 (2462 bp)
was obtained from Promega (Madison, WI). pcDNA3.1 (5428 bp)
and the E. coli strains Top 10 were purchased from Invitrogen.
An 897-bp SalI-HindIII fragment containing the EBV oriP-FR
region and basal CMV IE promoter from plasmid PDC312Nor-
iPNluc was subcloned into the SalI-HindIII sites of the pSP72
plasmid to create pSP72-oriP. The polyA sequence was amplified
by PCR from the pcDNA3.1 plasmid and subcloned into the
downstream of the oriP promoter in pSP72-oriP plasmid to create
pSP72-oriP-polyA. The IFNc gene was amplified by PCR from the
pShuttle-IFNc plasmid and subcloned into the pSP72-oriP-polyA
plasmid to create intermediate plasmid pSP72-oriP-IFNc. Parent
plasmid p2FC31-oriP-IFNc (11.3 kb) (Figure 1B) was constructed
by inserting the 1.6-kb SalI-oriP-IFNc-polyA-SpeI fragment from
the above intermediate plasmid pSP72-oriP-IFNc into the XhoI-
SpeI sites of p2FC31 (SalI and XhoI are isocaudamers).
Intermediate plasmid pSP72-oriP-luci was constructed by
replacing IFNc gene of pSP72-oriP-IFNc with luciferase gene
obtained from plasmid PDC312-oriP-luc. Then parent plasmid
p2FC31-oriP-luci (12.5 kb) was constructed by inserting the 2.8-kb
SalI-oriP-luciferase-polyA-SpeI fragment from the above interme-
diate plasmid pSP72-oriP- luci into the XhoI-SpeI sites of p2FC31.
Intermediate plasmids pSP72-CMV-IFNc and pSP72-CMV-luci
were constructed by replacing oriP promoter of pSP72-oriP-IFNc
and pSP72-oriP-luci with CMV promoter amplified by PCR from
the pcDNA3.1 plasmid, respectively. Then parent plasmids
p2FC31-CMV-IFNc (11.1 kb) and p2FC31-CMV-luci (12.3 kb)
were constructed by inserting the 1.4-kb SalI-CMV-IFNc-polyA-
ApaI fragment and 2.6-kb SalI-CMV-luciferase-polyA-ApaI frag-
ment from the above intermediate plasmids into the XhoI-ApaI sites
of p2FC31, respectively. All constructs were confirmed by DNA
sequencing (Figure 1).
Production and purification of minicircles
Minicircle-IFNc and minicircle-luciferase were produced accord-
ing to the methods described by Chen et al. [24] with minor
modifications. Briefly, overnight bacterial growth from a single
colony of parent plasmid-transformed E. coli Top 10 in Tris-borate
medium was centrifuged at 20uC and 4,000 rpm for 20 minutes.
The pellet was resuspended 4:1 (v/v) in fresh Luria-Bertani broth
containing 1.5% L-arabinose.The bacteria were incubated at 32uC
with constant shaking at 250 rpm for 4 hours. After adding one-
half volume of fresh Luria-Bertani broth (pH 8.0) containing 1.0%
L-arabinose, the incubation temperature was increased to 37uC,
and the incubation was continued for an additional 4 hours.
Episomal DNA circles were prepared from bacteria using plasmid
purification kits from Qiagen (Chatsworth, CA).
Quantitative evaluation of mc-oriP-luciferase or mc-CMV-
luciferase expression
To evaluate transgene expression from mc-oriP-luciferase or mc-
CMV-luciferase in EBV-negative and -positive cells, luciferase
activity was measured using the Dual-Luciferase Reporter Assay
System (Promega). Cells were seeded in 24-well culture plates
(5610
4 cells/well for C666-1, and 3610
4 cells/well for other cells).
After one doubling, cells were cotransfected with mc-oriP-luciferase
and pGL4.73 (Promega) simultaneously at a ratio of 50:1 (Table 1).
Cell lysates were analyzed for luciferase activity using the Dual-
Luciferase Reporter Assay System and a Luminometer (BERT-
HOLD Technologies, Centro LB-960) according to the manufac-
turers’ protocols [12].
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expression
To evaluate transgene expression from mc-oriP-IFNc or mc-
CMV-IFNc in EBV-negative and -positive cells, the concentration
of IFNc in the culture supernatant of transfected cell lines
was measured with a human IFNc ELISA kit (R&D Systems,
Minneapolis, MN) according to the manufacturer’s protocol. The
culture supernatant of transfected cells treated with mc-IFNc for
48 hours (C666-1 for 72 hours since its low growth rate) was
collected and frozen (270uC) for activity analysis [13]. The
sensitivity of the kit was up to 16 pg/ml.
Effect of mc-oriP-IFNc or mc-CMV-IFNc on cell viability
To evaluate the effect of mc-oriP-IFNc or mc-CMV-IFNc
treatment on viability, the WST assay was used as described
previously [13,36]. WST assay was performed using Cell Counting
Kit-8 which was nonradioactive, allowed sensitive colorimetric
assays for the determination of the number of viable cells in cell
proliferation and cytotoxicity assays. In brief, EBV-negative
and -positive cell lines were transfected with mc-oriP-IFNc
and corresponding control plasmids (Table 1). After 48 hours
(72 hours for C666-1), cell viability was measured with the Cell
Counting Kit-8 (Dojindo Molecular Technologies, Inc., Gaithers-
burg, MD) according to the manufacturer’s instructions.
Transfections and RNA interference
Transfections were conducted according to the manufacturer’s
instructions with minor modifications. Briefly, to generate CNE-2
cells expressing EBNA1 transiently, 2610
5 cells were transfected
with 5 mg of the EBNA1 expressing plasmid pLNCX2/EBNA1
using 5 mL of lipofectamine 2000 (Invitrogen). For RNA inter-
ference experiments, 3610
5 C666-1 cells were transfected with the
indicated amounts of siRNA against GFP (GCAAGCUGACC-
CUGAAGUUCAU) or against EBNA1 (GGAGGUUCCAAC-
CCGAAAU) using 5 mL of lipofectamine 2000 [37,38]. Twenty-
four hours later, cells were split for either subsequent transfection
or RT-PCR analysis.
RNA preparation and reverse transcription-PCR
Total RNA was prepared using the Micro-to-Midi Total RNA
Purification System (Invitrogen) according to the manufacturer’s
instructions. RNA was submitted to DNase digestion and 1 mg
aliquots were used for reverse transcription with the Reverse
Transcription System (Promega). PCR reactions were performed
using the following primers: human GAPDH, sense 59-AGA-
AGGCTGGGGCTCATTTG-39 and antisense 59-AGGGGCC-
ATCCACAGTCTTC-39; and human EBNA1, sense 59-AAG-
GAGGGTGGTTTGGAAAG-39 and antisense 59-TGGAATAG-
CAAGGGCAGTTC-39. The PCR reaction for EBNA1 was
carried out using the following conditions: denaturation—95uC
(30 s), annealing—62uC (30 s), and extension—72uC (30 s), with
40 cycles [37]. For GAPDH, the following reaction conditions
were used: denaturation—95uC (30 s), annealing—58uC (30 s),
and extension—72uC (30 s), with 25 cycles. The sizes of the PCR
products were 258 bp for GAPDH and 206 bp for EBNA1,
respectively. ImageJ software was used for quantitative analysis
of EBNA1/GAPDH from three independent experiments.
Antitumor activity of mc-oriP-IFNc in a subcutaneous
NPC tumor model
Care, use, and treatment of all animals in this study were in
strict agreement with the institutionally approved protocol
according to the USPHS Guide for the care and use of laboratory
animals, as well as the guidelines set forth in the Care and Use of
Laboratory Animals by the Sun Yat-sen University.
Female BALB/c nude mice (4–6 weeks old) were obtained from
Shanghai Slike Experimental Animals Co. Ltd. (Shanghai, China;
animal experimental license no. SCXKhu2007–0005). After 1 week
of adaptation, the mice were inoculated s.c. in the scapular region
with 2610
6 CNE-2 cells or 1610
7 C666-1 cells to generate tumors
for the following experiments. Once the tumor dimension reached
approximately 5–8 mm (100 mm
3), the animals were randomly
assigned to groups. Each mouse was treated with intratumoral
injection of 100 ml plasmid-liposome complex once a week for 3
weeks, according to the regimen shown in Table 1. For the
antitumor experiments, a total of 30 mice were used for either
xenograft model (6 mice per group, 5 groups). Tumor volume (V)
was measured and calculated according to the following formula: V
=L 6W
2/2 (L, length; W, width). Tumors were resected at the end
point and frozen (270uC) for analysis. For survival studies, there
wereeight mice in each group. Five treatment groups were included
for either xenograft model. Animals were either found dead or
sacrificed when tumors were observed by palpation to approach
10% of the body weight or when individual animals seemed to be
stressed by weight loss, ruffled fur, and/or lethargy. All the animal
experiments were conducted in accordance with the Guidelines for
the Welfare of Animals in Experimental Neoplasia [13].
IFNc production by minicircle-IFNc transfected tumor
tissues
Frozen samples were sonicated in 16TBS (25 mmol/L Tris,
138 mmol/L NaCl, and 3 mmol/L KCl, pH 7.4) and centrifuged
at 8,0006g for 1 minute. The resulting supernatants were used
for analysis. IFNc levels were determined using a human IFNc
ELISA kit (R&D Systems) according to the manufacturer’s
recommendations.
Antibodies and immunohistochemistry
The following commercial antibodies were used: IRF-1 (Beijing
Biosynthesis Biotechnology Co., Ltd, China), p21 and BAK (Boster
Biological Technology Ltd, Wuhan, China), Firefly Luciferase
(Abcam Inc, UK). Sections of 5 mm from formalin-fixed and
paraffin-embedded tumors were deparaffinized in two 5-min
washes with xylene and rehydrated through a graded alcohol series
to distilled water. The sections were then treated with 0.3% H2O2
in methanol for 15 min to block endogenous peroxidase activity.
Before applying the primary antibody, sections were microwaved
for antigenretrievalin 10 mmol/L citratebuffer(pH 6.0)for a total
of 25 min, followed by equilibration in phosphate-buffered saline.
Sections were treated first at room temperature for 30 minutes with
goat serum blocking solution (Boster Biological Technology Ltd,
Wuhan, China) in humidity chambers and then incubated with the
respective primary antibody for 12–16 h at 4uC. After several
washes, the sections were treated with the appropriate secondary
antibody (Envison Kit; DAKO) for 30 min. The antigen-antibody
complex was visualized by incubation with the DAB Kit (Envison
Kit; DAKO). Finally, all sections were counterstained with
hematoxylin. All immunostaining was first optimized in single
tissue slides. Negative controls were obtained using the method as
described above but without incubation with the appropriate
primary antibody [39,40,41,42,43].
Statistical analysis
All results were evaluated using Student’s t test with SPSS 11.0
software (SSPS, Inc., Chicago, IL). The survival results were
evaluated using Kaplan-Meier curves. p,0.05 was considered
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experiments are shown, and the data were presented as mean 6 SD.
Supporting Information
Figure S1 Immunohistochemical staining of tumor and
liver cells expressing luciferase. CNE-2 or C666-1 s.c.
tumors were intratumoral injected with 15 mg of either mc-oriP-
luci or mc-CMV-luci. The mice were sacrificed 72 hours after
treatment, and representative images of tumor and liver sections
stained for luciferase were obtained. Tissue sections are shown at
6200 magnification. Scale bar represents 50 mm.
(TIF)
Figure S2 Antitumor effect of mc-oriP-IFNc compared
with conventional plasmid pSP72-oriP-IFNc. pSP72-oriP-
IFNc versus p2WC31, p , 0.05 at days 11, 16, and 21; mc-oriP-
IFNc versus p2WC31, p , 0.05 at days 11, 16, and 21; pSP72-oriP-
IFNc versus mc-oriP-IFNc, p , 0.05 at days 16 and 21. *, p , 0.05,
pSP72-oriP-IFNc-treated group compared with the mc-oriP-IFNc-
treated group.
(TIF)
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